News Focus
News Focus
Followers 59
Posts 7595
Boards Moderated 0
Alias Born 10/20/2014

Re: BioBS2012 post# 282723

Thursday, 06/25/2020 7:45:04 AM

Thursday, June 25, 2020 7:45:04 AM

Post# of 448150
AMRN will lay a great Cardiovascular medication to waste if it
continues with the misguided strategy of GIA! Vascepa should be one
of the most used medications of all time, but only if it is placed
in the hands of BP! Adam Feuerstein warned that AMRN was playing
on Cardiovascular turf...and that JT could become a "Wall Street Hero"
if he were to sell AMRN to BP. Did JT ever receive any credible BO
offers? (Rumours were that offers were made and that JT may have
decided they were inadequate.) Perhaps JT truly believed AMRN was
worth far more than any BP was willing to pay. Vascepa is still a
great drug...and may be very valuable if it is in the right hands.
If Vascepa is left in the wrong hands, it runs the risk of being
"laid to waste." If JNJ owned Vascepa there would be speculation
of Vascepa's potential to ameleorate residual inflammation as a
result of COVID-19. How ironic that not only may the full potential
of Vascepa to treat CVD might be missed...but also its potential
to help heal from the ravages of COVID-19 as well.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News